A Smartphone-Based App to Improve Adjuvant Treatment Adherence to Multidisciplinary Decisions in Patients With Early-Stage Breast Cancer: Observational Study (Preprint)
Preprint
- 28 January 2021
- preprint
- Published by JMIR Publications Inc. in JMIR Preprints
Abstract
BACKGROUND Multidisciplinary treatment (MDT) and adjuvant therapy are associated with improved survival rates in breast cancer. However, nonadherence to MDT decisions is common in patients. We developed a smartphone-based app that can facilitate the full-course management of patients after surgery. OBJECTIVE This study aims to investigate the influence factors of treatment nonadherence and to determine whether this smartphone-based app can improve the compliance rate with MDTs. METHODS Patients who had received a diagnosis of invasive breast cancer and had undergone MDT between March 2013 and May 2019 were included. Patients were classified into 3 groups: Pre-App cohort (November 2017, before the launch of the app); App nonused, cohort (after November 2017 but not using the app); and App used cohort (after November 2017 and using the app). Univariate and multivariate analyses were performed to identify the factors related to MDT adherence. Compliance with specific adjuvant treatments, including chemotherapy, radiotherapy, endocrine therapy, and targeted therapy, was also evaluated. RESULTS A total of 4475 patients were included, with Pre-App, App nonused, and App used cohorts comprising 2966 (66.28%), 861 (19.24%), and 648 (14.48%) patients, respectively. Overall, 15.53% (695/4475) patients did not receive MDT recommendations; the noncompliance rate ranged from 27.4% (75/273) in 2013 to 8.8% (44/500) in 2019. Multivariate analysis demonstrated that app use was independently associated with adherence to adjuvant treatment. Compared with the patients in the Pre-App cohort, patients in the App used cohort were less likely to deviate from MDT recommendations (odds ratio [OR] 0.61, 95% CI 0.43-0.87; P=.007); no significant difference was found in the App nonused cohort (P=.77). Moreover, app use decreased the noncompliance rate for adjuvant chemotherapy (OR 0.41, 95% CI 0.27-0.65; P<.001) and radiotherapy (OR 0.49, 95% CI 0.25-0.96; P=.04), but not for anti-HER2 therapy (P=.76) or endocrine therapy (P=.39). CONCLUSIONS This smartphone-based app can increase MDT adherence in patients undergoing adjuvant therapy; this was more obvious for adjuvant chemotherapy and radiotherapy.Keywords
All Related Versions
- Published version: Journal of Medical Internet Research, 23 (9), e27576.
This publication has 38 references indexed in Scilit:
- Adherence to Intravenous Chemotherapy in African American and White Women With Early-Stage Breast CancerCancer Nursing, 2015
- A Lot of Action, But Not in the Right Direction: Systematic Review and Content Analysis of Smartphone Applications for the Prevention, Detection, and Management of CancerJournal of Medical Internet Research, 2013
- Factors influencing adherence to cancer treatment in older adults with cancer: a systematic reviewAnnals of Oncology, 2013
- Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider–patient communicationBreast Cancer Research and Treatment, 2012
- Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic reviewBreast Cancer Research and Treatment, 2012
- Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countriesAnnals of Oncology, 2011
- Treatment non-adherence in teenage and young adult patients with cancerThe Lancet Oncology, 2011
- Do Multidisciplinary Meetings Follow Guideline-Based Care?Journal of Oncology Practice, 2010
- Patient adherence and persistence with oral anticancer treatmentCA: A Cancer Journal for Clinicians, 2009
- Patient noncompliance with self-administered chemotherapyCancer, 1990